UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of March 2018
Commission File Number: 001-38097
ARGENX SE
(Translation of registrant’s name into English)
Willemstraat 5
4811 AH, Breda, the Netherlands
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
EXPLANATORY NOTE
On March 26, 2018, argenx SE issued a press release announcing that the European Commission has granted orphan status for the use of ARGX-113 for the treatment of myasthenia gravis in Europe. This press release is enclosed hereto as Exhibit 99.1 and is incorporated herein by reference.
Enclosed hereto as Exhibits 99.2, 99.3, 99.4, 99.5, and 99.6 and incorporated herein by reference are copies of the formal notice of convocation, agenda, and other ancillary documents relevant for argenx SE’s Annual General Meeting of Shareholders that will be held on Tuesday, May 8, 2018 at 10:00 a.m. (CET), at Hilton Amsterdam Airport Schiphol, Schiphol Boulevard 701, 1118 BG Schiphol, the Netherlands.
EXHIBITS
Exhibit | | Description |
| | |
99.1 | | Press Release titled “argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe” dated March 26, 2018 |
99.2 | | Press Release titled “argenx announces Annual General Meeting of Shareholders on May 8, 2018” dated March 26, 2018 |
99.3 | | Notice of Convocation for the Annual General Meeting of Shareholders of argenx SE to be held on May 8, 2018 |
99.4 | | Proxy Form for the Annual General Meeting of Shareholders to be held on May 8, 2018 |
99.5 | | Agenda for the Annual General Meeting of Shareholders to be held on May 8, 2018 |
99.6 | | Explanatory Notes for the Annual General Meeting of Shareholders to be held on May 8, 2018 |
99.7 | | Voting Instruction Form for holders of American Depositary Shares for the Annual General Meeting of Shareholders to be held on May 8, 2018 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ARGENX SE |
| |
Date: March 26, 2018 | By: | /s/ Dirk Beeusaert |
| | Dirk Beeusaert |
| | General Counsel |
3
